Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect

Xiaoqian Lan, Hongyan Zhuang, Pengfei Li · 2026

Read Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect by Xiaoqian Lan, Hongyan Zhuang, Pengfei Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219813.txt.

Description

Xiaoqian Lan, Hongyan Zhuang, and Pengfei Li report a negative result on a prescribing workaround for antipsychotic side effects in a 2026 study. The antipsychotic amisulpride raises prolactin, a hormone whose excess can disrupt periods, fertility, and bone health. Clinicians add aripiprazole, a drug with an opposite grip on the dopamine system, hoping it will pull prolactin back down, but proof for amisulpride specifically was missing.

Reviewing records from a psychiatric hospital between 2022 and 2025, the team compared prolactin levels in the week before patients started add-on aripiprazole with levels a week after. The average change was small and insignificant, and splitting the patients by sex or diagnosis changed nothing. Removing any patient from the analysis, one at a time, never altered the conclusion, so no outlier was driving the result. Until evidence arrives, the authors advise caution about expecting this combination to rescue patients from prolactin elevation.

Catalog record

CREATORXiaoqian Lan, Hongyan Zhuang, Pengfei Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13219813

Browse the full library · About the Tower of Babel